The White House on Wednesday said pharmaceutical firms risked damaging their reputations with big price hikes, but it sidestepped commenting directly on Mylan NV's decision to raise the price of its severe allergy treatment drug EpiPen. "I'm obviously not going to make specific comments to specifically second guess the pricing strategy … of one private enterprise," White House spokesman Josh Earnest said at a news briefing. There's no justification for these price hikes. Earlier today, the American Medical Association and U.S. Democratic presidential nominee Hillary Clinton urged Mylan to rein in what the AMA called the "exorbitant cost" of EpiPens. A spokesperson for Pfizer Canada, which distributes EpiPens in Canada, said the price has not changed.

Source: CBC News August 24, 2016 18:41 UTC